NCCN 11th Annual Congress: Hematologic Malignancies™

New York, NY US
September 30, 2016 to October 1, 2016

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Agenda

Target Audience

This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

Myeloproliferative Neoplasms and Myelofibrosis: Evolving Management      
• Discuss the clinical evidence supporting the use of JAK2 inhibitors in the management of myelofibrosis.
• Develop an individualized treatment plan for PMF incorporating the currently approved JAK2 inhibitor based on the risk stratification and symptom assessment.

Does Generic Imatinib Change the Treatment Approach in CML?    
• Describe the current standard of care and the impact of generic imatinib for the management of newly diagnosed   patients with CML.
• Identify the challenges associated with the selection of appropriate first-line TKI therapy for the management of patients with CML.

AML: Are We Finally Making Real Progress?      
• Identify the targeted therapies emerging for treatment of AML and discuss how the efficacy of these agents may be dependent on specific subpopulations of AML.

Case Presentations and Panel Discussion (Elderly AML, Slow Responding or Emerging Mutation CML, “Incidental” Identification of a JAK2 Mutant Clone)    
• Describe the clinical challenges in managing patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.
• Develop an evidence-based approach for the management of patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.

Case Presentations and Panel Discussion (Nasal NK-T cell, Adult T-cell Leukemia/ Lymphoma, Primary Cutaneous Gamma-delta T-cell Lymphoma)    
• Identify the clinical challenges in managing patients with nasal NK-T cell, ATLL, and primary cutaneous gamma-delta T-cell lymphoma.
• Develop an evidence-based approach for the management of patients with nasal NK-T cell, ATLL, and primary cutaneous gamma-delta T-cell lymphoma.

How I Treat Peripheral T-cell Lymphoma      
• Summarize the current and evolving treatment options for the treatment of PTCL.
• Develop an evidence-based treatment plan integrating novel agents for the management of newly diagnosed and relapsed PTCL.

Supportive Care in the Management of T-cell Lymphomas    
• Review the treatment-related toxicities and the supportive care measures used for their prevention and management in patients with CTCL.
• Identify the risk factors for tumor lysis syndrome (TLS) and develop an effective management strategy for its management in patients with PTCL.

Diffuse Large B-cell Lymphoma: Is Cell of Origin Necessary for Treatment Selection?    
• Describe the molecular heterogeneity of DLBCL and its implications in the management of DLBCL.
• Discuss the evidence from clinical trials on the use of novel therapeutic strategies and how these strategies can be incorporated into current treatment paradigms.

Early-stage Classical Hodgkin Lymphoma (CHL): Can We Eliminate Radiation Therapy for Most Patients?    
• Describe the challenges associated with the management of early stage CHL and the need to develop individualized treatment options.
• Review the evidence from recent clinical trials evaluating the use of chemotherapy alone for early stage CHL.

Shared Decision Making at Key Points in the Management of Hematologic Malignancies    
• Describe key decision points in the management of various hematologic malignancies.
• Discuss the effect on patient outcomes of shared clinician-patient decision making at key decision points.

Case Presentations and Panel Discussion (Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma with Renal Failure)
• Identify the clinical challenges in managing patients with smoldering myeloma, MGUS and multiple myeloma with renal failure.
• Develop an evidence-based approach for the management of patients with smoldering myeloma, MGUS and multiple myeloma with renal failure.

Multiple Myeloma: Diagnosis and Primary Treatment    
• Apply the updated criteria for diagnosis of multiple myeloma.
• Understand the data supporting newer treatment options in patients with newly diagnosed multiple myeloma.

How to Integrate the New Drugs into Therapy of Myeloma    
• Incorporate the new regimens in the clinical management of patients with multiple myeloma.

Getting Patients through Therapy: Supportive Care in Multiple Myeloma    
• Identify the classic clinical presentation and symptoms of multiple myeloma.
• Identify nursing interventions to provide supportive care for patients with multiple myeloma.
• Outline supportive care strategies for patients with multiple myeloma.

ALL: New Options for Relapsed Disease    
• Review the clinical data and discuss ongoing trials that are evaluating immunotherapy in the setting of relapsed or refractory ALL.

Debate—Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy    
• Discuss the evidence from clinical trials supporting the use of chemoimmunotherapy and TKI therapy for newly diagnosed patients with CLL.
• Identify patients with CLL who could be candidates for first-line therapy with TKIs and develop an individualized treatment plan for patients with newly diagnosed CLL.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Acerta Pharma - A member of the AstraZeneca Group
  • Ariad Pharmaceuticals, Inc.
  • Astellas
  • Celgene Corporation
  • Genentech
  • Gilead Sciences, Medical Affairs
  • MEI Pharma
  • Novartis Pharmaceuticals Corporation
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer
  • Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
  • Seattle Genetics, Inc.
  • Takeda Oncology

This activity is supported by an independent educational grant from AbbVie.

Support provided by Actelion Pharmaceuticals US, Inc.

This activity is supported by educational funding provided by Amgen.

Supported by an independent educational grant from Incyte.

Course summary
Available credit: 
  • 9.00 ACPE contact hours
  • 9.00 AMA PRA Category 1 Credit™
  • 8.24 ANCC contact hours
  • 9.00 Participation
Course opens: 
09/28/2016
Course expires: 
11/15/2017
Event starts: 
09/30/2016 - 6:00pm
Event ends: 
10/01/2016 - 5:00pm
Cost:
$0.00
New York Marriott Marquis
1535 Broadway
New York, NY 10036
United States

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 8.24 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 9.00 contact hours (0.90 CEUs) of continuing education credit in states that recognize ACPE-accredited providers.

Universal Activity Numbers: 0836-0000-16-086-L01-P through 0836-0000-16-101-L01-P

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 9.00 hours of Category I credit for completing this program.

Available Credit

  • 9.00 ACPE contact hours
  • 9.00 AMA PRA Category 1 Credit™
  • 8.24 ANCC contact hours
  • 9.00 Participation

Accreditation Period

Course opens: 
09/28/2016
Course expires: 
11/15/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing